Tumor Immunology and Immunotherapy

Tumor Immunology and Immunotherapy

Edited by Robert C. Rees

Abstract

This resource provides an up-to-date and comprehensive account of cancer immunity and immunotherapy, and discusses our adaptive and innate immunity to cancer, the mechanisms underpinning our immune response, current approaches to cancer immunotherapy, and how tumour and host responses can circumvent effective anti-cancer immunity. It then examines recent results, publications and current areas of interest including 'immune editing' and the specific issues that are affecting the research and development of vaccines, providing insight into how these problems may be overcome.

Bibliographic Information

Publisher:: Oxford University Press

Print Publication Date:: May 2014

Print ISBN-13:: 9780199676866

Published online:: Jul 2014

DOI:: 10.1093/med/9780199676866.001.0001

Author

Robert C. Rees, editor Director and Professor of Tumour Biology, The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK

Back to results

Print
Save
Cite
Email this content

Share Link

Copy this link, or click below to email it to a friend
Email this content
or copy the link directly:

https://oxfordmedicine.com/abstract/10.1093/med/9780199676866.001.0001/med-9780199676866
Link copied successfully

The link was not copied. Your current browser may not support copying via this button.
Share This

Disclaimer

Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.

Front Matter
- Dedication
- Foreword
- Preface
- Acknowledgements
- Abbreviations
- Contributor List
Chapter 1 Adaptive T-cell immunity and tumor antigen recognitionPedro Romero and Pierre G Coulie
Chapter 2 Impact of ageing and body mass on cancer immunotherapy outcomesGail D Sckisel, Arta M Monjazeb, Annie Mirsoian, Anthony E Zamora, Steven Grossenbacher, and William J Murphy
Chapter 3 The potential of natural killer cells in cancer immunotherapyThomas CC Tan, Jean-Marc Doisne, and Francesco Colucci
Chapter 4 The tumor microenvironment: The role of tumor-associated macrophages in cancer progression and responses to therapyRussell Hughes and Munitta Muthana
Chapter 5 ‘Hard’ and ‘soft’ loss of MHC class I expression in cancer cellsNatalia Aptsiauri, Angel M. Garcia-Lora, and Federico Garrido
Chapter 6 Modulation of the adaptive immune system through chronic inflammation and T-regulatory responsesAngus G Dalgleish
Chapter 7 Myeloid-derived suppressor cells: Immune-suppressive cells that facilitate tumor progression and promote and deter cancer-associated inflammationPratima Sinha, Virginia Clements, Meghan Burke, Catherine Fenselau, and Suzanne Ostrand-Rosenberg
Chapter 8 Triggering death receptors to promote cancer cell deathThomas J Sayers and Neil A Cross
Chapter 9 Identification of tumor antigens for clinical evaluationJayakumar Vadakekolathu, Amanda K Miles, David J Boocock, and Stephanie EB McArdle
Chapter 10 Viral antigens as targets for prophylactic and therapeutic intervention in cancerPeter L Stern and Kenneth Oguejiofor
Chapter 11 HER2/neu as a target for vaccine and antibody-directed therapiesConstantin N Baxevanis and Sonia A Perez
Chapter 12 Pre-clinical evaluation of immunotherapy: The case for prostate cancer and the TRAMP modelMatteo Bellone, Sara Martina Parigi, and Elena Jachetti
Chapter 13 Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapyPer thor Straten, David Schrama, Jürgen C Becker, and Mads Hald Andersen
Chapter 14 Predictive biomarkers to better select patients for cancer immunotherapyMarius Strioga and Eric Tartour
Chapter 15 Viral platforms for expression of tumor antigens in cancer immunotherapyKarishma Rajani, Vanesa Alonso-Camino, Nicolas Boisgerault, and Richard Vile
Chapter 16 Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignanciesPaul Moss
Chapter 17 DNA vaccinesLindy G Durrant, Wei Xue, Lee R Machado, Rachael L Metheringham, and Victoria A Brentville
Chapter 18 Programming the immune system through childhood infections: MUC1 tumor-associated antigen (TAA) as a disease-associated antigen (DAA)Uzoma K Iheagwara, Pamela L Beatty, Bianca Su-Wan Chan, Lora H Rigatti, Ted Ross, and Olivera J Finn
Chapter 19 Vaccination against myeloid leukaemias using newly defined antigensSusanne Hofmann, Ghazala Khan, Viktoriya Boncheva, Jochen Greiner, and Barbara-ann Guinn
Chapter 20 Immune-checkpoint blockade in cancer immunotherapyPatrick A Ott and F Stephen Hodi
Chapter 21 Multi-peptide cancer vaccines for clinical applicationHarpreet Singh-Jasuja, Toni Weinschenk, and Steffen Walter
Chapter 22 Adoptive T-cell therapy using TILs for the treatment of metastatic melanomaMarco Donia, Eva Ellebæk, and Inge Marie Svane
Chapter 23 Chimeric antigen receptor gene therapy in cancerJohn S Bridgeman and David E Gilham
Chapter 24 The vaccinal effect of monoclonal antibodies in cancer therapyClaire Deligne, Sophie Sibéril, and Jean-Luc Teillaud
Chapter 25 Antibody therapies: defining appropriate cell surface epitopes for targeting tumorsGabriele Multhoff and Michael Stanglmaier
Chapter 26 Adoptive lymphocyte (stem cell) therapy in cancerSophie Derniame and Aurore Saudemont
Chapter 27 Cancer stem cells (CSCs) and epithelial-to-mesenchymal transition (EMT): Tumor cell plasticity challenges immunotherapyTarik Regad and Morgan G Mathieu
Chapter 28 Immune escape and ageing of the immune system compromises the immune response to tumor antigensLudmila Müller and Graham Pawelec
End Matter
- Index

Browse All

Browse All

Browse All

Tumor Immunology and Immunotherapy

Edited by Robert C. Rees

Abstract

Bibliographic Information

Author

Share Link

Contents

Browse All

Browse All

Browse All

Recently viewed (0)

Recently viewed (0)

Tumor Immunology and Immunotherapy

Edited by Robert C. Rees

Abstract

Bibliographic Information

Author

Share Link

Contents